Toshihiko Kinoshita1, Kohji Shirai, Motohiro Itoh. 1. Department of Obstetrics and Gynecology, Sakura Hospital, Toho University School of Medicine, 564-1 Shimoshizu, Sakura City, Chiba 285-8741, Japan. kino@sakura.med.toho0u.ac.jp
Abstract
BACKGROUND: Lipoprotein lipase (LPL) mass is present in pre-heparin serum, although its activity is rarely detected. To clarify the dynamics of pre-heparin LPL mass during pregnancy, we studied the relationship between pre-heparin LPL mass and lipids in normal pregnant women. METHODS: Pre-heparin LPL mass and serum lipid levels were measured in 99 pregnant women during all three trimesters. RESULTS: When compared with the first and second trimesters, a significant decrease in pre-heparin LPL mass was observed in the third trimester. Plasma triglycerides were negatively correlated with pre-heparin LPL mass (r=-0.30; p<0.05). In contrast, LDL-C, HDL-C and total cholesterol did not exhibit a statistically significant correlation. CONCLUSION: The decrease in pre-heparin LPL mass is manifested only during the third trimester.
BACKGROUND:Lipoprotein lipase (LPL) mass is present in pre-heparin serum, although its activity is rarely detected. To clarify the dynamics of pre-heparinLPL mass during pregnancy, we studied the relationship between pre-heparinLPL mass and lipids in normal pregnant women. METHODS: Pre-heparinLPL mass and serum lipid levels were measured in 99 pregnant women during all three trimesters. RESULTS: When compared with the first and second trimesters, a significant decrease in pre-heparinLPL mass was observed in the third trimester. Plasma triglycerides were negatively correlated with pre-heparinLPL mass (r=-0.30; p<0.05). In contrast, LDL-C, HDL-C and total cholesterol did not exhibit a statistically significant correlation. CONCLUSION: The decrease in pre-heparinLPL mass is manifested only during the third trimester.
Authors: Elaine C Tsai; Judy A Brown; Megan Y Veldee; Gregory J Anderson; Alan Chait; John D Brunzell Journal: BMC Pregnancy Childbirth Date: 2004-12-20 Impact factor: 3.007
Authors: Daniel Eppel; Michael Feichtinger; Tina Lindner; Grammata Kotzaeridi; Ingo Rosicky; Guelen Yerlikaya-Schatten; Wolfgang Eppel; Peter Husslein; Andrea Tura; Christian S Göbl Journal: Acta Diabetol Date: 2021-01-02 Impact factor: 4.280